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Abstract
Background: Where P. vivax and P. falciparum occur in the same population, the peak burden of P. vivax infection and
illness is often concentrated in younger age groups. Experiences from malaria therapy patients indicate that immunity is
acquired faster to P. vivax than to P. falciparum challenge. There is however little prospective data on the comparative risk of
infection and disease from both species in young children living in co-endemic areas.
Methodology/Principal Findings: A cohort of 264 Papua New Guinean children aged 1-3 years (at enrolment) were actively
followed-up for Plasmodium infection and febrile illness for 16 months. Infection status was determined by light microscopy
and PCR every 8 weeks and at each febrile episode. A generalised estimating equation (GEE) approach was used to analyse
both prevalence of infection and incidence of clinical episodes. A more pronounced rise in prevalence of P. falciparum
compared to P. vivax infection was evident with increasing age. Although the overall incidence of clinical episodes was
comparable (P. falciparum: 2.56, P. vivax 2.46 episodes / child / yr), P. falciparum and P. vivax infectious episodes showed
strong but opposing age trends: P. falciparum incidence increased until the age of 30 months with little change thereafter,
but incidence of P. vivax decreased significantly with age throughout the entire age range. For P. falciparum, both
prevalence and incidence of P. falciparum showed marked seasonality, whereas only P. vivax incidence but not prevalence
decreased in the dry season.
Conclusions/Significance: Under high, perennial exposure, children in PNG begin acquiring significant clinical immunity,
characterized by an increasing ability to control parasite densities below the pyrogenic threshold to P. vivax, but not to P.
falciparum, in the 2nd and 3rd year of life. The ability to relapse from long-lasting liver-stages restricts the seasonal variation
in prevalence of P. vivax infections.
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Introduction
The epidemiology of P. falciparum malaria suggests immunity
might be acquired in ‘stages’, with children first acquiring
immunity against severe disease after relatively few episodes/
infections [1,2]. Uncomplicated falciparum disease, on the other
hand, remains common throughout most of childhood and a
significant decrease in risk of infection is only seen in adolescence
and early adulthood [1,3,4,5]. Similar age-dependent patterns of
disease are also observed for P. vivax. In highly endemic areas, such
as New Guinea, the risk of severe P. vivax disease is highest among
children less than 2 yrs of age [6,7], while uncomplicated P. vivax
illness is rare among children over 5 yrs [5,6] even though
infections are commonly found even in adolescents and adults
[3,8,9,10]. Interestingly, compared to P. falciparum, the prevalence
of infection with P. vivax peaks at younger ages [3,8,9,10],
contributes proportionally less to the burden of febrile illness [11]
in older children, adolescents and adults and the risk of severe
complications decreases faster with age [6,7].
Differences in the epidemiology of P. falciparum and P. vivax have
also been described in neighboring Vanuatu [12] and other areas
of the world where the species co-exist [13,14]. These epidemi-
ological observations are consistent with data from malaria
therapy patients that showed that immunity to P. vivax is more
rapidly acquired than immunity to P. falciparum [15]. Whereas a
single infection with P. vivax resulted in a strongly reduced
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incidence of febrile episodes upon homologous and to a lesser
extent heterologous re-infection [16], most secondary P. falciparum
infections were associated with fever, and in some cases high
density parasitemia, even if re-infected with the same strain [17].
Similar patterns were observed under natural conditions in Sri
Lankan patients [18].
Together, all these data indicate that under natural, lifelong
exposure, immunity to P. vivax is acquired more quickly than
immunity to P. falciparum and that different mechanisms may be
responsible for protection against severe disease than those that
protect against infections per se and mild episodes of disease
[1,19]. Although many potential targets and mechanisms of
protective immunity have been identified for both P. falciparum
[1,19,20,21,22] and P. vivax [23,24,25], we still know little about
the actual mechanisms involved in the acquisition of protective
immunity against either species and how these relate to the
observed difference in the speed of immune acquisition.
A recent study in Papua New Guinean children 5–14 yrs of age
found that despite acquiring a similar number of new blood stage
infections with P. falciparum and P. vivax, children had attained very
high levels of clinical immunity to P. vivax but remained at
significant risk of uncomplicated P. falciparum illness [5]. This was
linked to a greater ability to control P. vivax parasitaemia at levels
well below the pyrogenic threshold than for P. falciparum. The
control of parasite densities also increased with age in P. falciparum,
but a significant reduction in risk was only evident for high density
and symptomatic infections.
Immunological studies conducted as part of this cohort study
showed that the control of P. vivax infections was linked to the
acquisition of antibodies against the P. vivax Duffy binding protein
(PvDBP). In particular, children with high levels of blocking
antibodies to region 2 of PvDBP had a 55% reduced risk of
acquiring light-microscopy positive P. vivax infections [26].
Protection against clinical (and high density) P. falciparum infection
was mediated by both humoral [27] (Richards, Mueller, Beeson,
unpublished observations) and cellular immune responses [28,29].
In order to describe the epidemiological patterns of infection
and disease with P. falciparum and P. vivax and to identify factors
associated with either risk or protection from infection and disease,
we conducted a longitudinal cohort study of 264 Papua New
Guinean children, aged 1–3 years at enrolment. The study design
combined repeated blood sampling and molecular detection of
parasitemia with a large array of classical and functional immune
assays and thus provided an excellent opportunity to examine
epidemiological evidence of different rates of acquisition of
immunity to P. falciparum and P. vivax and investigate possible
mechanisms of immune protection.
Methods
This study was approved by institutional review boards of the
PNG Medical Research Advisory Committee (Approval 05.19),
University Hospitals Case Medical Center (Cleveland, Ohio USA),
and the Swiss Tropical Institute.
Field Site
This study was conducted in 11 villages in the Ilaita area of
Maprik District, East Sepik Province (Figure 1). Ilaita is situated at
the northern edge of the Sepik River plain in the foot hills of the
Torricelli Mountains, 80 km WSW of the provincial capital
Wewak. The area is highly endemic for all 4 human malaria
species, with P. falciparum the predominant parasite in all age
groups except children #3 yrs where P. vivax is more common
[10]. The study area is serviced by a single health sub-centre at
Ilaita 2 run by the South Sea Evangelical Church Health Services
and a government aid post at Sikamo near Sunuhu 1 (Figure 1).
All villages are within less than 2 hrs walk (i.e. 5 km) of either
health facility. Bednet use in the study area is heterogeneous, with
coverage ranging from 0% (Sunuhu 2) to 98% (Ilaita 5).
Enrolment
After obtaining community support and written parental
consent, 190 children aged 1–3 yrs from Ilaita 1–7 and Sunuhu
1 and 2 were enrolled in March 2006. Demographic information
was collected from all participating children and the location of
each child’s home was recorded using a hand-held GPS receiver
(Garmin 12XL). Each child was clinically examined: axillary
temperature was measured using digital thermometers, spleen
palpated and a standard questionnaire of common signs and
symptoms of malarial illness was administered. Hemoglobin (Hb)
was measured using a portable device (HemoCueH, A˚ngholm,
Sweden). A 5 ml venous blood sample was collected using
Heparin-VacutainerH tubes (Becton Dickinson, NJ, USA) and 2
blood slides (thick and thin films) made for determination of
malarial infection. Bed net usage of both mother and child was
queried. All children with parasitologically confirmed malaria (see
below) were treated with CoartemH (arthemeter-lumefantrine);
those with moderate to severe anaemia (i.e. Hb ,7.5 g/dl)
received an antimalarial treatment (CoartemH) plus 4 weeks of
iron and folate supplementation according to national treatment
guidelines.
As the initial enrolment did not yield the required sample size,
the study area was extended to include Kamanokor and Ingamblis
villages and 74 further children were enrolled into the study from
the 1st to the 3rd regular bleed time points (May to September
2006).Enrolment procedures were identical with the exception of
the 5 ml venous blood sample, which was not collected from these
later enrolments. A 250 ml finger prick blood sample was collected
instead.
Active Follow-Up
After enrolment all children were actively followed-up for a
maximum of 69 weeks. Every 2 weeks children were visited in
their home villages and clinically examined using a standard
questionnaire of signs and symptoms of malaria as well as a
catalogue of danger signs based on the PNG approach to
integrated management of childhood illness (IMCI). If the child
was febrile (axillary temperature .37.5uC) and/or reported signs
or symptoms of a febrile illness in the last 48 hrs or severe
anaemia, a 250 ml finger prick blood sample was collected, two
blood slides were made and Hb measured. An CIT Malaria (CIT
Diagnostics, Cape Town, South Africa) rapid diagnostic test
(RDT) was performed in all children with symptoms of malaria.
All RDT results were confirmed by light microscopy within
24 hrs. All malaria RDT/light microscopy positive children were
treated with CoartemH. All children with moderate-to-severe
anaemia (Hb ,7.5 g/dl) were given 4 weeks of iron and folate
supplementation and in cases with positive blood films treated
with CoartemH. Any children with signs of a severe illness were
transported to the Ilaita Health centre or where appropriate to
Maprik hospital. The guardians of all children were queried in
regards to bednet use and illness episodes during the preceding 2
weeks. All reported illness episodes were cross-checked with the
child’s health book and dates and types of medication received by
each child recorded.
In addition to fortnightly active surveillance for morbidity, all
children were actively checked for the presence of malarial
infection every 8 weeks using finger prick blood sampling. In
Malaria in Young PNG Children
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order to improve the detection of low-level infections, children
were visited on two consecutive days. If the child could not be
found on the second day, the study team revisited the child’s
family 3 and/or 5 days after the first follow-up visit. On both
days, a 250 ml finger prick blood sample was collected, two blood
slides were made and Hb measured. A malaria RDT was only
performed if the child was febrile and or reported signs or
symptoms of a febrile illness. Children with parasitologically
confirmed malarial illness or Hb ,7.5 g/dl were treated in the
same way as those detected during active morbidity surveillance.
On the first follow-up day the child’s spleen was palpated and the
guardian queried in regards to bednet use and illness episodes
during the preceding 2 weeks.
In total, children were followed for a maximum of 8 periods
each spanning 3 fortnightly morbidity surveillance visits and an 8
weekly cross-sectional bleed visit. Due to public holidays (Easter,
Independence week, Christmas, Easter) and the National General
Election (July 2007), active follow-up had to be suspended for 561
week and 5 of 32 active follow-ups were thus conducted at a 3-
week instead of a 2-week interval. As a consequence, 5 cross-
sectional bleeds occurred at a 9 instead of 8-week interval. At the
last cross-sectional bleed (i.e. week 69), the children were seen only
once and a single 5 ml venous blood sample was collected instead
of two consecutive finger prick samples.
Passive Case Detection
During the entire follow-up period, a passive case detection
system was maintained at the Ilaita health sub-centre and Sikamo
aid post. All study children attending the outpatient clinic at Ilaita
health centre were referred to specific study staff based at the
health centre for clinical and parasitological assessment. Following
a detailed clinical assessment, a 250 ml finger prick sample was
collected, 2 blood slides made, Hb measured and a RDT
performed in children showing signs or symptoms of malaria.
Similar to ill children detected during active follow-up, only
children with RDT or microscopy confirmed malaria illness were
treated with CoartemH. Children with signs of severe illness were
admitted to the health center inpatient wards or referred to
Maprik Hospital. Study children attending Sikamo aidpost were
attended to by the resident community health worker (CHW).
Figure 1. Schematic map of study area including participants’ house (dots), health centres (crosses), roads (black lines) and rivers/
streams (blue lines).
doi:10.1371/journal.pone.0009047.g001
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Following a more basic clinical assessment, she performed RDTs
on all suspected malarial cases and collected 2 blood slides and a
filter paper blood spot. The CHW was instructed to only treat
RDT positive children according to national treatment guidelines
with Amodiaquine (3d) plus sulphadoxine pyrimethamine (stat)
and refer negative children to either the IMR study team (if in the
vicinity) or to the Ilaita health center for further investigation.
Despite good coverage of active and passive surveillance, a small
number of children received treatment outside the study, either
because they attended Ilaita health center after hours or because
they sought treatment at a health facility outside the study area. All
treatment dates and drugs given were entered into a specific
database based on the children’s health books and cross-checked
with treatment information reported during active follow-up.
Laboratory Methods
Plasma and peripheral blood mononuclear cells (PBMCs) were
extracted from all venous blood samples. The remaining blood
cells were pelleted and aliquoted accordingly. Finger-prick blood
samples were separated into plasma and cell pellets. DNA was
extracted using the QIAamp 96 DNA Blood kit (Qiagen Inc.,
Valencia, CA, USA) from the cell pellet fraction of all samples.
All research blood films were read independently by two expert
microscopists. Slides with discrepant results were re-read by a 3rd
microscopist. Thick blood films were examined by light micros-
copy (LM) for 100 thick-film fields (under 100X oil immersion
lens) before being declared infection-negative. Parasite species in
positive films were identified and densities recorded as the number
of parasites per 200 white blood cells (WBC). Densities were
converted to the number of parasites per ml of blood assuming
8,000 WBC per ml (population average WBC count [3]). Slides
were scored as LM-positive for an individual Plasmodium species, if
the species was detected independently by at least 2 microscopists
and/or subsequent PCR-based analysis confirmed the presence of
the species. Densities were calculated as the geometric mean
densities of all positive reads.
The presence of each of the four human malaria species was
assessed in all blood samples using a semi-quantitative post-PCR,
ligase detection reaction/fluorescent microsphere assay (LDR-
FMA)[30]. This assay combines PCR amplification of the small
subunit (ssu) ribosomal RNA gene (491–500 bp fragments) using
genus specific primers, followed by a multiplex species-specific
ligation detection reaction (LDR). The design and sensitivity of
this assay has been described previously [9,30,31]. In order to
guarantee maximum sensitivity for the detection of Plasmodium
infections, the PCR-cycle number was set at 35. Cut-off values for
positivity were set at the 99%-quantile of signals in negative
controls as in Mueller et al [10].
Paired blood samples from 8-weekly cross-sectional double
bleeds showed significant variance in the detection of malarial
parasites both in LDR-FMA and LM diagnosis. In 35.3% of
children infected with P. falciparum and in 27.4% of those infected
with P. vivax, the infection was only detected by LDR-FMA in one
of the two samples (data not shown). A comparable level of day-to-
day variation in detection was observed in LM diagnosis. For those
time points with blood samples on consecutive days, a combined
diagnostic reading was calculated in the following way: i) a child
was considered positive for any given Plasmodium species if it was
positive on at least 1 day and ii) the density of the infection was
defined as the higher of the two densities.
Statistical Analyses
The analyses of both prevalence of infection and incidence of
clinical episodes were based on a generalised estimating equation
(GEE) approach that allowed accurate modelling of both the
variation in the outcomes and the correlations between repeated
measurements in individual children.
The prevalence of infection at the 8 or 9 weekly bleed time
points were analysed using logistic GEE models via the
XTLOGIT procedure in STATA 8.0. Preliminary analyses
showed that the correlations between measurements in individual
children were best modelled using an exchangeable correlation
structure. A semi-robust Huber/White/sandwich estimator of
variance was used to assure valid standard errors. Best fitting
models were determined by backward elimination using Wald’s
Chi-square tests for individual variables. The analyses of age and
spatial trend and predictors of infection were based exclusively on
data from double bleed time points (i.e. weeks 9–60) using the
combined diagnostic results from both samples (see above). As only
one sample was collected at baseline and final bleeds (i.e. weeks 0
and 69), only prevalence data from the first sample collected at
double bleed time points was used for the analyses of time trends
across the entire time of follow-up. Difference in log-transformed
parasite densities among age groups were analysed using a normal
GEE model with exchangeable correlation structure and semi-
robust variance estimator.
For estimation of incidence of clinical episodes in each 8 or 9
week follow-up interval, clinical malaria episodes were defined as a
fever (i.e. axillary temperature .37.5uC) or history of fever during
the last 48 hrs in the presence of a light microscopically detectable
parasitaemia observed in either passive or active follow-up. Febrile
episodes with only LDR-FMA detectable parasitaemia were not
considered to be malarial episodes. A density cut-off value for
clinical disease was set based on a pyrogenic threshold of 2500
parasites/ml for P. falciparum and 500 parasites/ml for all other
species [32]. Moderate and high density episodes were defined as
febrile episodes with parasitaemias exceeding the pyrogenic
threshold 4 and 20-fold, respectively. For each interval, children
were considered at risk from the 1st day after the 2nd or only blood
sample was taken. Cross-sectional bleed days were thus considered
part of the preceding interval and clinical episodes detected during
the cross-sectional bleeds were included in that interval. Children
were not considered at risk for 2 weeks after treatment with
CoartemH and 4 weeks after treatment with AQ plus SP.
As preliminary analyses showed significant overdispersion in the
number of episodes per child, a negative binomial model GEE
model (based on XTNBREG procedure) was used for the analyses
of incidence rates. As in the other GEE models, an exchangeable
correlation structure and semi-robust variance estimator were used
and best fitting models determined by backward elimination using
Wald’s Chi-square tests for individual variables. Differences in
participant characteristics at enrolment were assessed using Chi-
square and Fisher’s exact tests. All analyses were done using the
STATA 8 statistical software package (College Station, TX).
Results
Enrolment
Between March and September 2006, a total of 293 children 1–
3 yrs of age (63 months) were screened for inclusion into the
study. Of these, 21 were excluded from enrolment due to chronic
illness, permanent disability or because they were severely
malnourished. An additional 8 children were excluded post
enrolment either because their guardians withdrew consent within
less than 8 weeks from enrolment (n = 6) and/or because they had
very poor and erratic attendance (n = 2). Of the 264 children in the
final cohort, 190 were enrolled at study start in March 2006 and
74 over the following 6 months (Figure 2).
Malaria in Young PNG Children
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At enrolment, children were between 0.91–3.21 yrs of age
(median 1.70, Inter-quartile range (IQR): [1.27, 2.43] and 118
(43.9%) were female. There were no differences in demographic
characteristics between early and later enrolled children (p.0.5).
Plasmodium infections were diagnosed in 199 (75.4%) and 168
(63.6%) children by post-PCR LDR-FMA and light microscopy
(LM), respectively. P. vivax was the most common parasite (LDR-
FMA: 53.0% LM: 44.3%) followed by P. falciparum (LDR-FMA:
49.6% LM: 32.6%). P. malariae (LDR-FMA: 9.9% LM: 4.2%) and
P. ovale (LDR-FMA: 2.7%, LM: 0.0%) were present but relatively
rare. Mixed species infections were detected in 85/199 (42.7%)
LDR-FMA and 45/168 (26.8%) LM positive children. There were
no significant differences in the prevalence of P. falciparum infection
between early and late enrolments (p.0.09). While later
enrolments did have a significantly higher prevalence of P. vivax
(LDR: 50.0% vs 63.5%, p = 0.033; LM: 40.0% vs 55.4%,
p = 0.024) at the time of enrolment, the prevalence of P. vivax
infection in late enrolled children was comparable to that observed
in concurrently collected samples from earlier enrolled children
(p.0.05).
A high degree of morbidity was observed during enrolment.
Sixty-four children (23.9%) presented with an axillary temperature
.37.5uC or were reported to be suffering from a febrile illness. Of
these, 54 (85.94%) had concurrent LM-positive malarial infections
of any density compared to 56.5% of afebrile children (Odds-ratio
(OR): 4.71, CI95 [2.14, 11.38], p,0.001), with 44 (68.8%)
exceeding 2500 parasites/ml for P. falciparum and 500/ml for non-
falciparum infections (14 Pf, 21 Pv, 2 Pm and 7 Pf plus Pv). Mean
Figure 2. Prevalence of malaria at regular cross-sectional surveys: A) first samples only, B) double bleed samples 24 hrs apart, C)
study retention profile.
doi:10.1371/journal.pone.0009047.g002
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haemoglobin level was 8.90 g/dl with 19.7% (52/264) of children
diagnosed with moderate-to-severe anaemia (Hb ,7.5 g/dl). Late
enrolments were significantly more likely to suffer from fever (OR:
2.17 CI95 [1.14, 4.08.38], p = 0.01), malaria (any density OR: 2.23
CI95 [1.13, 4.32], p = 0.011) and/or anaemia (Hb ,7.5 g/dl, OR:
2.78 CI95 [1.40, 5.46], p = 0.001) than early enrolled children.
However, after adjusting for village of residence the observed
difference in morbidity among early and later enrolled children
was no longer statistically significant (p.0.1). Early and later
enrolled children were thus combined for all further analyses.
Children were then followed up for up to 69 weeks. 248 of 264
(93.9%) children were retained until the end of the study, 10 children
were lost during follow up and 3 were withdrawn by their parents
(Figure 2). 3 children died during the conduct of the study, 1 from heart
failure caused by severe malarial anaemia, 1 from severe malaria and 1
from dysentery, based on clinical diagnosis. Compliance with the study
protocol was very high. 96.0%–100.0% of children at risk were seen at
regular 8-weekly bleeds with 90.7%–99.6% of children seen on two
consecutive days at the week 9 to 60 bleeds. Attendance at the 2-weekly
active morbidity follow-up ranged from 88.6%–99.5%.
Parasitaemia during Follow-Up
After enrolment a gradual increase in the prevalence of
malarial infections was observed by both LDR-FMA and LM.
There were, however, pronounced differences in both overall
and seasonal trends between different Plasmodium species
(Figure 2). While increasing significantly during the course of
the study (non-parametric test for trend, p,0.01), P. falciparum
prevalence was highly seasonal (1st sample only, adjusted
for significant linear trend: LDR-MFA: X2 = 89.8, df = 5,
p,0.001, LM: X2 = 28.6, df = 5, p,0.001). By both methods of
detection, P. falciparum prevalence decreased significantly
during the dry season (May-Sept ‘06) and rose again rapidly
with the onset of the rains in Nov 06 with P. falciparum peaking in
Jan 07 (LDR: 61.8%, LM: 34.7%). Seasonal trends for P. vivax
were much less pronounced. When diagnosed by LDR-FMA, P.
vivax prevalence did show a significant increase over time
(p,0.01) with only weak evidence for seasonality (X2 = 10.8,
df = 5, p = 0.057). By LM no trend for increasing prevalence
was observed (p = 0.54), but P. vivax showed considerable
seasonality (X2 = 20.8, df = 5, p,0.001) with a significant
increase in prevalence through the dry season peaking in Sept
06’ (53.5%) and a pronounced drop in prevalence in the early
rainy season (Jan ’07: 35.8%). Among children with two
consecutive samples, seasonal trends were even stronger for P.
falciparum but less evident for P. vivax (Figure 2). By LDR-FMA,
significant increases over time were also observed for P. malariae
(p = 0.02) and P. ovale (p,0.01), with seasonal trends
of P. malariae (X2 = 16.5, df = 5, p = 0.005) and P. ovale
(X2 = 10.8, df = 5, p = 0.057) parallel to those exhibited by
P. falciparum and P. vivax, respectively.
Besides time trends, there was also significant spatial variation in
the prevalence of malarial infections (Tables 1 & 2). Prevalence
rates were highest in villages furthest from the Ilaita Health centre
(i.e. Sunuhu 1&2, Kamanokor, Ilaita 5 and Ingamblis). Spatial
variation was more pronounced for P. falciparum (LDR-FMA:
X2 = 58.9, df = 10, p,0.001: LM: X2 = 36.3, df = 10, p,0.001)
compared to P. malariae (LDR-FMA: X2 = 23.6, df = 10, p = 0.008;
LM: X2 = 14.2, df = 10, p = 0.14) and P. vivax (LDR-FMA:
X2 = 19.9, df = 10, p = 0.031: LM: X2 = 14.4, df = 10, p = 0.16).
Incidence of Clinical Disease
Over the 69 weeks of follow-up, a total of 1134 febrile episodes
(incidence rate (IR) 4.60 / child / yr) with parasitaemia (by light
microscopy) were observed. Of these 842 (IR 3.42) had a
concurrent parasitaemia .2,500 for P. falciparum and .500 for
non-falciparum infections. P. falciparum was the most common cause
of malarial illness (any density: 630 (IR 2.56), Pf .2,500: 472 (IR
1.92), Pf .10,000: 379 (IR 1.54), Pf .50,000: 206 (IR 0.84))
followed by P. vivax (any density: 605 (IR 2.46), Pv .500: 391 (IR
1.59), Pv .2,000: 271 (IR 1.10), Pv .10,000: 113 (IR 0.84)). P.
malariae (any density: 49 (IR 0.20)) and P. ovale (any density: 7 (IR
0.03)) episodes were rare. 161 of 1134 (14.2%) clinical episodes
were the result of mixed species infections of any density. Of the
842 infections that exceeded species-specific pyrogenic density cut-
offs, 59 were mixed infections (7.0%) where both species exceeded
the density threshold. P. falciparum / P. vivax mixed infections
accounted for 83.8% (135/161) of mixed infections of any density
and 84.7% (50/59) of mixed infections that exceeded the
pyrogenic parasitaemia thresholds. Detailed analyses on mixed
species interactions and their effect on risk of morbidity will be
presented elsewhere.
As seen for prevalence of infection, the incidence of malarial
episodes showed strong seasonality (Figure 3, Table 3 & 4). In
parallel with the prevalence of infections, incidence rates of P.
falciparum episodes decreased significantly (any density: X2 = 101.9,
df = 5, p,0.001, Pf .2500: X2 = 90.5, df = 5, p,0.001) during
the dry season reaching its lowest level in the Aug-Sept ’06 period
(any density: IR 1.27, Pf .2500: IR 0.99) before rising quickly
following the onset of rains in October and peaking in Dec‘06–Jan
’07 (any density: IR 4.13, Pf .2500: IR 3.39) before falling once
again towards the end of the rainy season in Apr - May ’07 (any
density: IR 1.95, Pf .2500: IR 1.39). The seasonal trends for
incidence of P. vivax episodes were comparable to those seen in P.
falciparum although the incidence of P. vivax peaked earlier in the
rainy season (Oct–Nov ’08, any density: IR 3.23, Pv .500: IR
2.38) before decreasing consistently during the remainder of the
rainy and into the dry season (any density: X2 = 53.3, df = 5,
p,0.001, Pv .500: X2 = 30.0, df = 5, p,0.001). Similar trends
were observed in the incidence of P. falciparum and P. vivax episodes
with higher parasite densities (Figure 3). The seasonal trends in P.
vivax episodes were thus at least partially uncoupled from those
seen for prevalence of P. vivax infection. No seasonal differences
were observed for episodes of P. malariae (X2 = 2.2, df = 5,
p = 0.82).
There was highly significant spatial variation in the incidence of
P. falciparum (Table 3, any density: X2 = 32.5, df = 10, p,0.001 Pf
.2500: X2 = 35.2, df = 5, p,0.001) and P. vivax (Table 4, any
density: X2 = 47.5, df = 10, p,0.001, Pv.500: X2 = 56.5, df = 10,
p,0.001) but not P. malariae episodes (any density: X2 = 7.4.0,
df = 10, p = 0.69). Areas with high P. falciparum and high P. vivax
incidence were significantly different with P. falciparum incidence
rates highest in Ilaita 1, Ilaita 5, Sunuhu 1&2 and Kamankor, while
P. vivax episodes were most frequent in villages near Ilaita health
centre such as Ilaita 2–4 and Ilaita 6 & 7.
Age Trends in Burden of Plasmodium Infections and
Disease
The prevalence of malarial infections was significantly associ-
ated with the age of the child (Figure 4). Using only data from
double bleed time points (i.e. weeks 9–60), the prevalence of P.
falciparum was found to increase significantly (X2 = 35.3, df = 2,
p,0.001) from children ,18 mth (LDR-FMA: 27.3%, LM:
12.3%) to children 18–23 mth (LDR-FMA 38.1%, LM: 19.3%)
and children 24–29 mth (LDR-FMA 54.3%, LM 32.2%), with no
further significant increase in older children (p = 0.24). For P. vivax,
a similar age pattern was observed for LDR-FMA (,18 mth:
57.6%, 18–23 mth: 67.3%, $24 mth 73.5%, X2 = 12.5, df = 2,
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p = 0.002) but not for LM diagnosed infections (X2 = 6.05, df = 5,
p = 0.30), while the prevalence of P. malariae continued to increase
significantly across the entire age range (LDR-FMA: X2 = 15.3,
df = 5, p = 0.009, LM: X2 = 18.1, df = 5, p = 0.003). Given the
non-linear nature of these age trends, 1st, 2nd and/or 3rd order
polynomials were used to model age trends in multivariate
analyses (Figure 4, Table 1 & 2). Among children with LM positive
infections, there was a significant decrease in geometric mean
Table 1. Multivariate predictors of malarial infection at double bleed time points as diagnosed by post-PCR LDR-FMA assay.
Any infection P. falciparum P. vivax P. malariae P. ovale
OR CI95 OR CI95 OR CI95 OR CI95 OR CI95
Village1
Ilaita 2 0.55 [0.19,1.61] 0.47 [0.24,0.90] 0.50 [0.22,1.16] 3.94 [1.67,9.28]
Ilaita 3 0.81 [0.28,2.37] 0.94 [0.52,1.68] 0.81 [0.38,1.75] 2.11 [0.78,5.74]
Ilaita 4 0.74 [0.26,2.12] 0.91 [0.55,1.50] 0.55 [0.26,1.17] 2.04 [0.82,5.05]
Ilaita 5 2.76 [0.86,8.87] 1.14 [0.55,2.38] 1.34 [0.55,3.30] 1.31 [0.46,3.77]
Ilaita 6 0.64 [0.22,1.85] 0.50 [0.22,1.14] 0.82 [0.36,1.87] 1.59 [0.43, .91]
Ilaita 7 0.85 [0.31,2.32] 1.00 [0.59,1.71] 0.53 [0.27,1.06] 2.03 [0.82,5.03]
Ingamblis 3.18 [1.11,9.15] 1.77 [0.93,3.37] 1.11 [0.55,2.27] 4.43 [1.70,11.6]
Kamanokor 4.65 [0.84,25.8] 3.36 [1.91,5.93] 0.93 [0.44,1.93] 4.42 [1.72,10.3]
Sunuhu 1 2.04 [0.70,5.93] 2.04 [1.25,3.35] 0.84 [0.42,1.69] 3.04 [1.28,7.23]
Sunuhu 2 1.88 [0.62,5.70] 1.89 [1.04,3.42] 1.14 [0.56,2.36] 2.30 [0.90,5.89]
p = 0.001 p,0.001 p = 0.031 p= 0.008
Month2
March 0.62 [0.40,0.96]
May 0.30 [0.21,0.43]
July 0.22 [0.14,0.34]
September 0.21 [0.14,0.33]
November 0.44 [0.29,0.66]
p,0.001
Year (’07) 2.83 [1.79,4.47] 1.44 [1.01,2.07] 0.70 [0.50,0.97]
p,0.001 p= 0.046 p= 0.035
Age
linear 62,791 10.1 [3.52,29.1] 4,898 1.43 [1.10,1.86] 1.35 [1.02,1.80]
quadratic 0.22 0.70 [0.58,0.86] 0.04 p = 0.008 p= 0.038
cubic 1.56 p,0.001 1.51
p,0.001 p,0.001
Prior Drug 0.59 [0.41,0.85] 1.68 [1.27,2.22] 0.64 [0.48,0.84]
p = 0.005 p,0.001 p = 0.002
Ill 2 weeks 0.57 [0.37,0.87] 0.55 [0.33,0.91]
p = 0.009 p= 0.021
ITN use3 0.43 [0.24,0.75] 0.62 [0.42,0.92] 0.51 [0.31,0.87]
p = 0.003 p = 0.018 p= 0.013
Anaemia
Hb (g/dl)3 0.59 [0.47,0.73] 0.66 [0.59,0.74]
Hb $8 g/dl p,0.001 p,0.001 2.44 [1.69,3.57]
p,0.001
Spleen 1.47 [1.25,1.74] 1.47 [1.24,1.75]
p,0.001 p,0.001
Febrile 1.63 [1.27,2.15] 0.62 [0.47,0.82]
p = 0.001 p = 0.001
GEE-model based estimates with semi-robust confidence intervals.
OR: Odds ratio. CI95: 95% confidence intervals
1Comparison level: Iliata 1. 2 Comparison level: January. 3 Average bed net usage as continuous variable. 4Per g/dl increase
doi:10.1371/journal.pone.0009047.t001
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densities of P. vivax (,18 mth: 1624/ml, 18–23 mth: 989/ml, 24–
29 mth: 614/ml, 30–35 mth: 484/ml, 36–41 mth: 475/ml,
$42 mths 315/ml, X2 = 44.75, df = 5, p,0.001) but not of P.
falciparum infections (,18 mth: 8042/ml, 18–23 mth: 2350/ml, 24–
29 mth: 4744/ml, 30–35 mth: 3576/ml, 36–41 mth: 3228/ml,
$42 mths 1353/ml, X2 = 10.80, df = 5, p = 0.055). Comparable
patterns were observed when only data from the 1st bleed were
considered.
Among infected children, there was a significantly higher prevalence
of febrile symptoms with P. falciparum (39.1%, OR = 3.49, CICI95[2.48,
7.40], p,0.001) and mixed P. falciparum / P. vivax infections (22.6%,
OR = 1.58, CI95[1.18, 2.12], p = 0.002) compared to P. vivax only
(15.5%) infections. Prevalence of febrile symptoms decreased signif-
icantly with age in children infected with P. vivax (OR (per year increase
in age) = 0.57, CI95[0.54, 0.85], p = 0.001) but not in P. falciparum or
mixed infections (OR = 0.97, CI95[0.77, 1.22], p = 0.77).
Table 2. Multivariate predictors of malarial infection at double bleed time points diagnosed by light microscopy.
Any infection P. falciparum P. vivax P. malariae
OR CI95 OR CI95 OR CI95 OR CI95
Village1
Ilaita 2 0.58 [0.23,1.51] 0.50 [0.22,1.16]
Ilaita 3 1.12 [0.47,2.68] 1.21 [0.67,2.18]
Ilaita 4 0.66 [0.31,1.43] 0.78 [0.40,1.52]
Ilaita 5 2.34 [0.80,6.79] 1.76 [0.70,4.38]
Ilaita 6 0.84 [0.36,1.96] 0.61 [0.27,1.38]
Ilaita 7 0.67 [0.32,1.39] 0.55 [0.24,1.23]
Ingamblis 1.67 [0.76,3.65] 1.36 [0.70,2.65]
Kamanokor 1.84 [0.77,4.36] 2.51 [1.43,4.40]
Sunuhu 1 1.65 [0.80,3.43] 1.92 [1.16,3.18]
Sunuhu 2 2.31 [1.10,4.86] 1.76 [0.98,3.16]
p,0.001 p,0.001
Month2
March 0.77 [0.49,1.21]
May 0.58 [0.39,0.86]
July 0.62 [0.39,0.99]
September 0.52 [0.33,0.81]
November 0.83 [0.52,1.33]
p = 0.023
Age
linear 19.9 [6.11,65.1] 35.4 [10.1,124] 1.19 [1.00,1.42]
quadratic 0.66 [0.52,0.83] 0.58 [0.46,0.74] p = 0.049 1.22 [1.13,1.31]
p,0.001 p,0.001 p,0.001
Prior Drug 0.22 [0.16,0.30] 0.30 [0.22,0.39]
p,0.001 p,0.001
Ill 2 weeks 0.51 [0.36,0.73] 0.50 [0.37,0.67] 0.26 [0.09,0.76]
p,0.001 p,0.001 p= 0.014
ITN use 0.52 [0.31,0.83] 0.62 [0.40,0.96] 0.53 [0.39,0.73]
p = 0.007 p= 0.033 p,0.001
Anaemia
Hb (g/dl) 3 0.58 [0.50,0.66] 0.52 [0.45,0.61] 0.64 [0.53,0.76]
Hb ,8 g/dl p,0.001 p,0.001 2.22 [1.52,3.23] p,0.001
p,0.001
Spleen 1.22 [1.04,1.46] 1.80 [1.47,2.19]
p = 0.018 p,0.001
Febrile 1.46 [1.00,2.08] 2.19 [1.60,3.00]
p = 0.047 p,0.001
GEE-model based estimates with semi-robust confidence intervals.
OR: Odds ratio. CI95: 95% confidence intervals
1Comparison level: Iliata 1. 2 Comparison level: January. 3 Average bed net usage as continuous variable. 4Per g/dl increase.
doi:10.1371/journal.pone.0009047.t002
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Although the overall incidence of malaria episodes did not vary
greatly with age (X2 = 9.4, df = 5, p = 0.095), the incidence of P.
falciparum and P. vivax episodes were strongly age dependent, albeit
with opposing trends (Figure 5). In parallel with prevalence of
infection, incidence of P. falciparum episodes rose significantly (any
density: X2 = 13.2, df = 2, p = 0.001, Pf .2500: X2 = 11.2, df = 2,
p = 0.004) from children,18 mth (any density: IR 1.50, Pf.2500:
IR 1.06) to children 18–23 mth (any density: IR 2.15, Pf.2500: IR
1.71) and children 24–29 mth (any density: IR 2.81, Pf .2500 IR
2.20), with no further significant increase in incidence there-
after (any density: X2 = 0.58, df = 3, p = 0.90, Pf.2500: X2 = 0.23,
df = 3, p = 0.97). No significant difference between age groups was
observed for high and very high density episodes (Pf .10,000:
X2 = 7.5, df = 5, p = 0.19, Pf.50,000: X2 = 1.52, df = 5, p = 0.47).
The incidence of P. vivax episodes, however, decreased significantly
with age throughout the entire age range (any density: X2 = 19.0,
df = 5, p = 0.002, Pv .500: X2 = 29.1, df = 5, p,0.001) from 3.07
(any density) and 2.13 (Pv .500) episodes / child / per year in
children,18 mths to 1.52 (any density) in children 36–41 mths and
0.59 (Pv.500) in children$42 mths. The observed decreases with
age were log-linear with decreasing incidence rate ratios (IRR, per
year increase in age) with increasing levels of parasitaemia (any
density, crude IRR = 0.75, CI95[0.65,0.85], p,0.001; Pv .500,
IRR = 0.59, CI95[0.49,0.71], p,0.001; Pv .2000, IRR =
0.55, CI95[0.44,0.69], Pv.10000, IRR = 0.50 CI95[0.38,0.71],
p,0.001). The incidence of P. malariae episodes increased
significantly with age (any density: IRR = 1.66, CI95 [1.22, 2.25],
p,0.001). These age effects remained significant when adjusted for
other factors (see Table 3&4).
Effects of Insecticide Treated Nets
Children who slept under insecticide treated bed nets (ITNs) had
significantly fewer malarial infections (Tables 1 and 2). However,
there were significant differences in ITN use (F10,252 = 22.90,
p,0.001) among villages with.80% usage in Ilaita 4 & 5, 58–80%
usage in the other Ilaita villages while in the more remote villages
only 0–35% of children reported sleeping under a bed net. This
unequal spatial distribution complicates the assessment of the
association of ITN use with risk of malarial infections and disease.
Adjusted for age and time trends, ITN usage was associated with a
significant reduction in prevalence of malarial infections with any of
the 4 malarial species diagnosed by LDR (Figure 6, Adjusted Odd
Ratio (AOR): Pf: 0.30, p,0.001; Pv: 0.61, p,0.001; Pm: 0.62,
p = 0.027; Po: 0.52, p = 0.015) and LM (AOR: Pf: 0.21, p,0.001;
Pv: 0.61, p = 0.001; Pm: 0.29, p = 0.002). Further adjusting for
difference in prevalence among villages significantly reduced the
association of ITN usage with prevalence of P. falciparum (AOR:
LDR: 0.67, p = 0.054; LM: 0.54, p = 0.009) and P. malariae (AOR:
LDR: 1.18, p = 0.508; LM: 0.65, p = 0.345) but not of P. vivax
(AOR: LDR: 0.64, p = 0.015; LM: 0.68, p = 0.066) and P. ovale
(AOR: LDR: 0.49, p = 0.070). Adjustment for other factors did not
significantly alter the associations of ITN with prevalence of
malarial infection (Figure 6, Tables 1 & 2).
Frequent use of ITNs also provided significant protection
against P. falciparum and P. malariae but not against P. vivax episodes
(Tables 3 & 4). Adjusted for age and time trends, ITN usage was
associated with a significant reduction in incidence of P. falciparum
(Figure 6, any density, Pf .2500 & Pf .10000: all aIRRs = 0.53,
p,0.001) and P. malariae episodes (any density: aIRR = 0.47,
p,0.001) but a significant increase in the risk of moderate to high
density P. vivax episodes (any density: aIRR = 1.24, p = 0.09; Pv
.500: aIRR = 1.56, p = 0.007; Pv .2000: aIRR = 1.88,
p = 0.001). When also adjusted for villages of residence, the
association of ITN usage with increased risk of P. vivax episodes
was no longer seen (any density: aIRR = 0.86, p = 0.41; Pv .500:
aIRR = 0.94, p = 0.80; Pv .2000: aIRR = 1.17, p = 0.58),
whereas the effect of ITNs on risk of P. falciparum (any density:
aIRR = 0.58, p = 0.003; Pf .2500: aIRR = 0.59, p = 0.011; Pf
.10000: aIRR = 0.54, p = 0.012) and P. malariae (any density:
aIRR = 0.64, p = 0.28) was unchanged. Adjustment for other
factors did not significantly alter the associations of ITN with risk
of malaria episodes (Figure 6, Tables 3 &4).
Other Predictors for Plasmodium Infection and Disease
Additional independent predictors for the presence of Plasmo-
dium infections at cross-sectional bleeds included confirmed
antimalarial treatment less than 4 weeks prior, reported febrile
illness in preceding 2 weeks, presence of a febrile illness and/or
enlarged spleen and hemoglobin (Hb) levels (Table 1 & 2). Recent
antimalarial treatments were associated with a significant decrease
in risk of P. vivax by both LDR and LM but an increase in risk of
LDR but not LM positive P. falciparum, while reported febrile
illness in the previous 2 weeks was associated with a significant
decrease in risk of LDR positive P. vivax and LDR and LM positive
P. malariae infections. The presence of febrile symptoms was
positively associated with P. falciparum infections while enlarged
spleens were found more often in children infected with P.
falciparum or P. malariae. Higher Hb levels were associated with a
decreased prevalence of P. falciparum and P. malariae (LM only) but
an increased prevalence of P. vivax infections.
Figure 3. Incidence of P. falciparum and P. vivax clinical episodes
with different parasitaemia threshold for individual 8/9 weekly
intervals.
doi:10.1371/journal.pone.0009047.g003
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Multivariate predictors of risk of clinical malaria also included
infection status, recent antimalarial treatment and Hb levels at the
start of the 8 week interval (Tables 3 & 4). For all types of clinical
episodes except high density P. vivax (Pv .2,000), the presence of
an infection at the start of the interval was associated with a
significant increase in risk of clinical episodes with the same
Plasmodium species during the following 8–9 weeks (adjusted
incidence rate ratio (aIRR): Pf 1.23–1.43, p = 0.028–0.002; Pv
1.44, p,0.001; Pm 5.28 p,0.001). Treatment with an antima-
larial no more the 4 weeks prior to the start of the follow-up period
resulted in a decrease in the incidence of clinical disease for low to
moderate density episodes of P. falciparum and P. malariae, but not
for P. vivax and high density P. falciparum episodes (Table 3 & 4).
Increasing Hb levels on the other hand were associated with an
increase in the risk of P. falciparum and P. vivax episodes (aIRR (per
g increase in Hb): Pf.2500: 1.11, p = 0.022; Pf .10,000: 1.14
p = 0.007; Pv .500: 1.15, p = 0.013, Pv .2000: 1.24, p = 0.002).
Discussion
The present study shows a significantly faster acquisition of
clinical immunity to P. vivax compared to P. falciparum in Papua
Table 3. Multivariate predictors of incidence of infections in 86 8/9 weeks intervals: All and P. falciparum episodes of different
parasite density.
All episodes Pf all Pf .2,500 Pf .10,000
IRR CI95 IRR CI95 IRR CI95 IRR CI95
Village1
Ilaita 2 0.77 [0.51,1.16] 0.48 [0.25,0.93] 0.47 [0.22,1.01] 0.49 [0.23,1.06]
Ilaita 3 1.14 [0.80,1.66] 0.62 [0.37,1.04] 0.55 [0.31,0.97] 0.48 [0.27,0.84]
Ilaita 4 0.92 [0.68,1.25] 0.58 [0.37,0.89] 0.43 [0.26,0.72] 0.41 [0.24,0.70]
Ilaita 5 0.73 [0.52,1.03] 0.96 [0.63,1.46] 0.76 [0.48,1.20] 0.55 [0.34,0.91]
Ilaita 6 1.13 [0.76,1.68] 0.59 [0.32,1.09] 0.41 [0.19,0.88] 0.35 [0.16,0.78]
Ilaita 7 0.89 [0.67,1.18] 0.65 [0.43,0.99] 0.41 [0.24,0.67] 0.35 [0.20,0.63]
Ingamblis 0.55 [0.40,0.75] 0.42 [0.26,0.67] 0.34 [0.20,0.57] 0.25 [0.14,0.42]
Kamanokor 0.91 [0.67,1.23] 0.98 [0.66,1.46] 0.81 [0.50,1.31] 0.68 [0.42,1.11]
Sunuhu 1 0.83 [0.62,1.11] 0.78 [0.52,1.17] 0.68 [0.42,1.08] 0.51 [0.31,0.83]
Sunuhu 2 0.77 [0.57,1.05] 0.76 [0.50,1.15] 0.67 [0.41,1.07] 0.48 [0.29,0.78]
p = 0.003 p,0.001 p,0.001 p,0.001
Month2
March 0.51 [0.41,0.63] 0.50 [0.39,0.65] 0.51 [0.38,0.70] 0.51 [0.36,0.72]
May 0.41 [0.34,0.50] 0.35 [0.26,0.46] 0.40 [0.28,0.56] 0.44 [0.30,0.65]
July 0.30 [0.23,0.41] 0.20 [0.13,0.30] 0.25 [0.15,0.41] 0.26 [0.15,0.43]
September 0.61 [0.46,0.81] 0.53 [0.37,0.75] 0.70 [0.46,1.08] 0.70 [0.43,1.14]
November 0.64 [0.48,0.85] 0.67 [0.48,0.93] 0.88 [0.58,1.32] 0.87 [0.56,1.35]
p,0.001 p,0.001 p,0.001 p,0.001
Year (’07) 0.61 [0.50,0.74] 0.59 [0.45,0.78] 0.69 [0.49,0.98] 0.70 [0.50,0.97]
p,0.001 p,0.001 p= 0.040 p= 0.035
Age
linear 1.35 [1.18,1.54] 1.20 [1.03,1.41]
quadratic p,0.001 p= 0.021
Infection status (at start of interval)
Any 1.73 [1.36,2.20]
Pf p,0.001 1.23 [1.02,1.48] 1.35 [1.10,1.64] 1.43 [1.14,1.80]
p = 0.028 p= 0.004 p= 0.002
Prior drug 0.78 [0.67,0.92] 0.77 [0.62,0.95]
p = 0.002 p= 0.015
ITN use3 0.77 [0.61,0.98] 0.59 [0.41,0.85] 0.58 [0.38,0.90] 0.54 [0.33,0.88]
p = 0.030 p= 0.005 p= 0.016 p= 0.013
Anaemia
Hb (g/dl)4 1.11 [1.05,1.16] 1.11 [1.02,1.22] 1.14 [1.04,1.26]
p,0.001 p= 0.022 p= 0.007
GEE-model based estimates with semi-robust confidence intervals.
IRR: Incidence rate ratio. CI95: 95% confidence intervals
1Comparison level: Iliata 1. 2 Comparison level: January. 3 Average bed net usage as continuous variable. 4Per g/dl increase.
doi:10.1371/journal.pone.0009047.t003
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New Guinean children aged 1–4 yrs of age. Despite comparable
numbers of clinical episodes with P. falciparum and P. vivax in this
age group, there was a highly significant drop in the incidence of
uncomplicated P. vivax episodes with increasing age but little signs
of any acquisition of protective immunity against uncomplicated P.
falciparum illness. On the contrary, the incidence of P. falciparum
illness increased in the 2nd year and remained constant during the
3rd and 4th years of life.
While the rise in the incidence of P. falciparum episodes went
hand in hand with a rise in the prevalence of P. falciparum infection,
a moderate increase in the prevalence of P. vivax infections was
observed despite a 72% drop in the incidence of P. vivax episodes
with a density exceeding a pyrogenic threshold of 500 parasites/ml
in children younger than 18 mth compared to those older than
42 mth of age. Both the geometric mean density of P. vivax
infections and the risk of febrile symptoms associated with the
presence of P. vivax infections decreased significantly with age,
indicating an increasing ability of older children to control P. vivax
density at levels below the pyrogenic threshold. Both the density of
P. falciparum infection and prevalence of febrile symptoms
Table 4. Multivariate predictors of incidence of infections in 868/9 weeks intervals: P. vivax and P. malariae episodes of different
parasite density.
Pv all Pv .500 Pv .2,000 Pm all
IRR CI95 IRR CI95 IRR CI95 IRR CI95
Village1
Ilaita 2 1.31 [0.75,2.31] 1.78 [0.88,3.62] 1.48 [0.60,3.65]
Ilaita 3 1.97 [1.18,3.30] 2.75 [1.51,5.03] 2.52 [1.19,5.31]
Ilaita 4 1.34 [0.87,2.06] 1.65 [0.91,3.01] 1.63 [0.77,3.43]
Ilaita 5 0.62 [0.38,1.00] 0.47 [0.23,0.95] 0.32 [0.13,0.80]
Ilaita 6 1.47 [0.80,2.58] 1.98 [1.00,3.94] 2.08 [0.89,4.88]
Ilaita 7 1.31 [0.87,1.98] 1.46 [0.82,2.64] 1.10 [0.51,2.34]
Ingamblis 0.56 [0.41,1.11] 0.54 [0.25,1.15] 0.40 [0.15,1.10]
Kamanokor 0.85 [0.53,1.37] 0.90 [0.49,1.64] 0.91 [0.43,1.94]
Sunuhu 1 0.78 [0.51,1.19] 0.96 [0.56,1.66] 0.80 [0.38,1.67]
Sunuhu 2 0.71 [0.45,1.11] 0.63 [0.34,1.18] 0.69 [0.31,1.55]
p,0.001 p,0.001 p,0.001
Month2
March 0.51 [0.36,0.71] 0.60 [0.42,0.84] 0.49 [0.32,0.75]
May 0.41 [0.28,0.58] 0.46 [0.32,0.67] 0.42 [0.26,0.67]
July 0.39 [0.25,0.62] 0.62 [0.42,0.90] 0.45 [0.28,0.73]
September 0.77 [0.50,1.21] 1.11 [0.78,1.58] 1.13 [0.73,1.76]
November 0.69 [0.43,1.11] 0.90 [0.61,1.33] 0.76 [0.47,1.24]
p,0.001 p,0.001 p,0.001
Year (’07) 0.66 [0.46,0.93]
p = 0.020
Age
linear 0.75 [0.64,0.87] 0.50 [0.42,0.59] 0.45 [0.36,0.57] 1.53 [1.13,2.06]
p,0.001 p,0.001 p,0.001 p= 0.005
Infection status (at start of interval)
Pv 1.44 [1.18,1.75] 1.44 [1.13,1.83]
Pm p,0.001 p,0.001 5.28 [2.91,9.58]
p,0.001
Prior Drug 1.21 [1.01,1.45] 1.37 [1.09,1.71] 1.67 [1.25,2.24] 0.47 [0.23,0.94]
p = 0.037 p= 0.007 p,0.001 p= 0.033
ITN use 0.51 [0.27,0.97]
p = 0.041
Anaemia
Hb (g/dl) 1.15 [1.03,1.28] 1.24 [1.08,1.43]
p = 0.013 p= 0.002
GEE-model based estimates with semi-robust confidence intervals.
IRR: Incidence rate ratio. CI95: 95% confidence intervals
1Comparison level: Iliata 1. 2 Comparison level: January. 3 Average bed net usage as continuous variable. 4Per g/dl increase.
doi:10.1371/journal.pone.0009047.t004
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associated with such infections did not vary significantly within the
age range covered by this study, indicating that even at 3–4 yrs of
age the ability to effectively control P. falciparum parasitaemias has
not yet been acquired.
The current study thus confirms and extends the finding of a
significantly faster rate of immune acquisition to P. vivax, as
described by Michon et al [5], to a different PNG population;
from children 5–14 yrs with a high degree of clinical immunity to
P. vivax to much younger children that are still at high risk of both
clinical P. falciparum and P. vivax disease. The patterns found in
the present cohort are also consistent with those observed in a
cohort of children under 10 years conducted in neighbouring
Vanuatu [12]. Despite a lower transmission than P. falciparum,
Maitland et al. also observed that the incidence of clinical P. vivax
episodes peaked in younger children (Pv: 1–2 yrs IR = 1.15
episodes per child per year vs Pf: 3–4 yrs IR = 0.93) and that
parasite densities in both symptomatic and asymptomatic P. vivax
but not P. falciparum infections decreased with age. Even at very
low transmission among Karen communities along the Thai-
Burmese border, P. vivax prevalence and incidence peak in
significantly younger age groups than P. falciparum [33]. It is thus
likely that the faster acquisition of immunity to P. vivax (compared
to P. falciparum) is a general phenomenon in people with life-long
natural exposure across a wide range of malaria transmission
intensities. Further studies in Thailand and Sri Lanka corroborate
this view [34,35].
The reasons for the faster acquisition of clinical immunity to P.
vivax are not well understood. It may simply be a function of the
higher burden of infection and illness in very early life. Two
specific aspects of P. vivax biology are likely to have contributed to
the higher overall prevalence of P. vivax infection and the lack of a
clear seasonality in the present cohort: its ability to re-establish
blood stage infections through relapses from long-lasting liver-
stages and its high transmissibility. P. vivax is known to produce
gametocytes as soon as a blood stage infection is established and at
low parasite density [36]. In PNG, the prevalence of P. vivax
gametocytes can exceed that of P. falciparum even when the
prevalence of asexual stages is lower[37]. Furthermore, P. vivax is
more infective to mosquitoes fed on blood collected at village
population surveys and comparable when fed on blood from
gametocyte positive outpatients [37]. In addition, younger, early
biting mosquitoes tend be more commonly infected by P. vivax
than P. falciparum [38] in particular in the presence of ITNs [39].
Such an increased transmissibility would facilitate both the early
establishment of P. vivax infection in young children and allow
sustained transmission through periods of reduced transmission
potential. In PNG, P. vivax is usually the most common infection in
infants and toddlers [9,10]. Once infections are established,
relapses from long-lasting liver-stages will occur regularly and
contribute significantly to a high rate of blood stage infections. In a
recent drug trial between 27% and 87% of PNG children 6–60
months of age treated for P. vivax or P. falciparum episodes had
recurrent asexual P. vivax parasitaemia within 42 days [40].
Data from US malaria therapy patients who received two P.
vivax infections indicate that immunity against re-infection with the
homologous P. vivax strain is acquired very rapidly. Both the
frequency and intensity of febrile episodes, as well as peak and
mean parasite densities, decrease by more than 80% during the
first 20 days of parasitaemia.[16]. The frequency of febrile
episodes also decreased by 48–55% in re-infections with a
heterologous strain with equal peak parasitaemias but lower mean
parasitaemias indicating the presence of a limited level of cross-
immunity. In patients infected with P. falciparum, immunity to
homologous P. falciparum re-infections developed more slowly while
no reduction in the development of fever or higher density
parasitaemia was seen upon heterologous challenge [17]. Similar
differences in the development of strain-specific and strain
transcending immunity were also observed in Romanian patients
[15]. The lower risk of febrile symptoms associated with P. vivax
infection during the dry season, when many infections are likely to
be due to relapses rather than primary infections, and conse-
quently the different seasonal trends of P. vivax infections and
disease observed in the present cohort, indicate that similar
differences in immune acquisition may also occur under conditions
of natural exposure.
The incidence of clinical episodes with any malarial species
during an 8 or 9 week interval was positively associated with the
presence of parasitaemia (with same species) at the start of the
interval, indicating that either ‘asymptomatic’ infections detected
during cross-sectional surveys may go on to become symptomatic
later on and/or that there is significant heterogeneity in
transmission among participants (i.e. children with an infection
during the cross-sectional survey are more likely to acquire new
infections with the same species than uninfected children).
Detailed genotyping of P. falciparum and P. vivax infections will be
needed to determine the respective contribution of persistent and
new infections to the burden of disease. The incidence of P.
Figure 4. Age dependence of risk of malarial infections: age-
prevalence at 7 cross-sectional survey time points with 2
consecutive bleeds 24 hrs apart. GEE model based estimates and
semi-robust standard errors for age categories. Fitted lines: best fitting
1st, 2nd or 3rd degree polynomials of age as continuous variable.
doi:10.1371/journal.pone.0009047.g004
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falciparum and P. malariae episodes was negatively associated with
receiving an antimalarial drug less than 4 weeks prior, but the
incidence of P. vivax episode was higher in children with a recent
treatment. This difference is most likely due to the very high rate
of recurrent P. vivax parastitaemia 4–6 weeks following treatment
with CoartemH or Amodiaquine plus sulphadoxine-pyrimeth-
amine [40].
Children who reported always sleeping under insecticide treated
bed nets (ITN) experienced 42% and 53% fewer episodes
(adjusted for other factors) of P. falciparum and P. malariae,
respectively than children who never reported using ITNs. Use
of ITNs was also associated with a significant decrease in the
prevalence of light microscopy positive P. falciparum but not with
LDR-FMA positive P. falciparum or P. malariae infections. These
results are remarkably similar to those obtained in randomised
control trials in Africa where sleeping under an ITN was
associated with a 50% decrease in risk of uncomplicated P.
falciparum illness and a 16% decrease in prevalence of P. falciparum
infection [41].
As in a randomised control trial in Thailand [42], the incidence
of clinical P. vivax malaria episodes was not significantly affected by
bed net use. The prevalence of P. vivax infections was however
significantly lower in children using ITNs. This paradoxical
pattern may be related to the unequal spatial distribution of ITNs
in the study area. ITNs are most common in villages that are close
to Ilaita health centre and thus have better access to health care.
These villages also have a higher incidence of P. vivax illness but
lower prevalence of P. vivax infections (by LDR-FMA) than villages
further away from the health centre.
The ease of access to health care may have a differential impact
on health seeking behaviour in relation to P. falciparum and P. vivax
illness. With increasing immunity the duration and severity of
fevers associated with P. vivax infection tend to decrease rapidly, in
particular for recurrences with the same strain either through re-
infection [16] or relapse. If access to health care is nearby, parents
seek treatment more quickly and for less severe symptoms than if
they have to walk several hours [43,44]. Parents of children in
more remote villages may thus have delayed treatment seeking for
low level fevers associated with P. vivax infection (e.g. from
relapsing parasites) until the study team next visited the villages. By
that time many of the symptoms would have resolved through
control of the infection by the immune system, negating the need
for antimalarial treatment. Due to the lower immunity to P.
falciparum, few P. falciparum episodes would have been mild and self-
limiting, prompting parents to more readily seek treatment even in
more remote villages and/or for symptoms to persist until the next
study team visit. These differences in treatment seeking are well in
line with the fact that P. vivax episodes were more commonly
detected amongst cases presenting to the health centre, while P.
falciparum episodes dominated during study visits (Lin & Mueller,
personal communication). A potential beneficial effect of ITNs on
incidence of P. vivax episodes would therefore have been off-set by
more active treatment seeking and easy access to treatment in
villages with high bed net usage. Conversely, frequent treatment of
P. vivax episodes is likely to have limited the establishment of
chronic, asymptomatic infections, thus resulting in a bias towards a
lower prevalence of P. vivax infections in villages near the health
centre.
The present study thus confirms the earlier findings of
significant differences in the acquisition of clinical immunity to
P. falciparum and P. vivax in children 5–14 yrs of age [5] in a cohort
of younger Papua New Guinean children (1–4 years) who
experience high levels of clinical illness with either Plasmodium
species. Despite similar overall incidences of clinical disease, the
incidence of P. vivax episodes starts to decrease significantly in the
2nd year of life when the incidence of P. falciparum episodes is still
rising. The acquisition of clinical immunity to P. vivax is
characterized by an increasing ability to control P. vivax
parasitaemia that is not apparent in P. falciparum infections. In
the age group studied (i.e. 1–4 yrs), there is thus clear evidence for
the acquisition of clinical immunity to P. vivax but not yet to P.
falciparum.
The exact nature of the processes underlying the observed
difference in immune acquisition remain to be elucidated but
differences in the interaction of parasite with the human red cell
are likely to play an important role. P. falciparum can avoid
clearance by the spleen through sequestration of infected RBC
into microvasculature via binding of variant surface antigens
Figure 5. Age dependence of risk of malarial illness: Effect of age
at start of 8/9 weeks follow-up period on incidence of malarial
illness with different parasite cut-offs. GEE model based estimates
and semi-robust standard errors for age categories. Fitted lines: best fitting
1st, 2nd or 3rd degree polynomials of age as continuous variable.
doi:10.1371/journal.pone.0009047.g005
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(VSA) to a variety of host receptors [45,46]. The continued
acquisition of immune responses against a broad range of VSAs is
thought to be critical for acquiring protective immunity against P.
falciparum illness and infection [22,47]. P. vivax does not have a
gene family homologous to PfEMP1, the most important group of
VSAs in P. falciparum [48]. The P. vivax multi-gene vir family is not
expressed clonally and different vir proteins are found concurrently
both on the RBC surface and in other parasite organs [49].
Although it has been hypothesised that vir-gene are involved in
avoidance of splenic clearance, the exact function of vir-proteins
remains to be determined[49].
P. falciparum is also known to use a variety of host receptors for
invasion of host red blood cells [50]. Despite a recent report of P.
vivax invading Duffy negative RBC (Me´nard, Barnadas &
Zimmerman, personal communication), efficient invasion of P.
vivax seems to require binding of the PvDBP to the Duffy antigen.
Antibodies blocking this interaction have been shown to confer a
high level of protection against P. vivax infection [26]. However,
high levels of PvDBP blocking antibodies are not commonly found
even among adults with complete clinical immunity to P. vivax,
indicating that immune responses directed against other parasites
antigens (or against other parts of the PvDBP protein) may be
more important for the acquisition of immunity to P. vivax under
natural exposure. If and how any differences in antigenic diversity
in such key antigens contribute to differential immune acquisition
between P. falciparum and P. vivax remains to be determined.
Detailed, comparative studies aimed at understanding these
differences in parasite biology and host immune responses to P.
falciparum and P. vivax are on-going. Such comparative studies on
immune acquisition to both P. falciparum and P. vivax species that
combine a rigorous, longitudinal study design with in-depth
immunological and parasitological assessments will provide
valuable insights into differences in immune targets and mecha-
nisms underlying acquisition of clinical immunity that may inform
malaria vaccine development and testing.
Acknowledgments
First and foremost, we could like to thank all study participants and their
families and the staff at Ilaita health centre and Sikamo Aid post. Without
their great support this work would not have been possible. We also thank
Magarina Bakandu, Judith Tawakra, Robin Nambili, Jack Larry, Merolyn
Uranoli and Samson Satofan for assistance with the field work, Moses
Lagog, Anselm Masalan, Maggie Raiko, Nandao Taronka and Lina Lori
for assistance with sample preparation and microscopy and Lawrence Rare
for coordinating community relations. Finally, we thank Dr. James Beeson
for critical comments leading to completion of this manuscript.
Author Contributions
Conceived and designed the experiments: PS IF LS PZ IM. Performed the
experiments: EL BK LG LR AL SS DS IB MBZ. Analyzed the data: EL
SD IM. Contributed reagents/materials/analysis tools: LG SD IF PZ.
Wrote the paper: EL LR IF LS PZ IM.
References
1. Marsh K, Kinyanjui S (2006) Immune effector mechanisms in malaria. Parasite
Immunol 28: 51–60.
2. Gupta S, Snow RW, Donnelly CA, Marsh K, Newbold C (1999) Immunity to non-
cerebral severe malaria is acquired after one or two infections. Nat Med 5: 340–343.
3. Genton B, Al Yaman F, Beck HP, Hii J, Mellor S, et al. (1995) The epidemiology
of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in
preparation for vaccine trials. I. Malariometric indices and immunity. Ann Trop
Med Parasitol 89: 359–376.
4. Genton B, Al Yaman F, Beck HP, Hii J, Mellor S, et al. (1995) The epidemiology
of malaria in the Wosera area, East Sepik Province, Papua New Guinea, in
preparation for vaccine trials. II. Mortality and morbidity. Ann Trop Med
Parasitol 89: 377–390.
5. Michon P, Cole-Tobian JL, Dabod E, Schoepflin S, Igu J, et al. (2007) The risk
of malarial infections and disease in Papua New Guinean children. Am J Trop
Med Hyg 76: 997–1008.
6. Genton B, D’Acremont V, Rare L, Baea K, Reeder JC, et al. (2008) Plasmodium
vivax and mixed infections are associated with severe malaria in children: a
prospective cohort study from Papua New Guinea. PLoS Med 5: e127.
7. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, et al. (2008)
Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a
prospective study in Papua, Indonesia. PLoS Med 5: e128.
8. Smith T, Hii JL, Genton B, Muller I, Booth M, et al. (2001) Associations of peak
shifts in age–prevalence for human malarias with bednet coverage. Trans R Soc
Trop Med Hyg 95: 1–6.
9. Kasehagen LJ, Mueller I, McNamara DT, Bockarie MJ, Kiniboro B, et al.
(2006) Changing patterns of Plasmodium blood-stage infections in the Wosera
region of Papua New Guinea monitored by light microscopy and high
throughput PCR diagnosis. Am J Trop Med Hyg 75: 588–596.
10. Mueller I, Widmer S, Michel D, Maraga S, McNamara DT, et al. (2009) High
sensitivity detection of Plasmodium species reveals positive correlations between
infections of different species, shifts in age distribution and reduced local
variation in Papua New Guinea. Malar J 8: 41.
11. Cox MJ, Kum DE, Tavul L, Narara A, Raiko A, et al. (1994) Dynamics of
malaria parasitaemia associated with febrile illness in children from a rural area
of Madang, Papua New Guinea. TransRSocTropMedHyg 88: 191–197.
12. Maitland K, Williams TN, Bennett S, Newbold CI, Peto TE, et al. (1996) The
interaction between Plasmodium falciparum and P. vivax in children on Espiritu
Santo island, Vanuatu. Trans R Soc Trop Med Hyg 90: 614–620.
13. Balfour MC (1935) Malaria studies in Greece. Am J Trop Med Hyg 15:
301–329.
14. Earle WC (1939) Epidemiology of malaria in Puerto Rico. Puerto Rico J Pub
Health Trop Med 15: 3–27.
Figure 6. Association of personal bed net use on risk of
malarial infections and disease. Closes circles: univariate estimates,
open triangle: adjusted for age and time trends, closed diamonds: age,
time and village adjusted, open squares: estimates from best fitting
model (see Table 1 & 2). All estimates from GEE model with semi-robust
standard errors.
doi:10.1371/journal.pone.0009047.g006
Malaria in Young PNG Children
PLoS ONE | www.plosone.org 14 February 2010 | Volume 5 | Issue 2 | e9047
15. Ciuca M, Ballif L, Chelarescu-Vieru M (1934) Immunity in Malaria. Trans R Soc
Trop Med Hyg 6: 619–622.
16. Collins WE, Jeffery GM, Roberts JM (2004) A retrospective examination of
reinfection of humans with Plasmodium vivax. Am J Trop Med Hyg 70: 642–644.
17. Collins WE, Jeffery GM (1999) A retrospective examination of secondary
sporozoite- and trophozoite-induced infections with Plasmodium falciparum:
development of parasitologic and clinical immunity following secondary
infection. Am J Trop Med Hyg 61: 20–35.
18. Gunewardena DM, Carter R, Mendis KN (1994) Patterns of acquired anti-
malarial immunity in Sri Lanka. Mem Inst Oswaldo Cruz 89: 63–65.
19. Schofield L, Mueller I (2006) Clinical immunity to malaria. Curr Mol Med 6:
205–221.
20. Yazdani SS, Mukherjee P, Chauhan VS, Chitnis CE (2006) Immune responses
to asexual blood-stages of malaria parasites. Curr Mol Med 6: 187–203.
21. Wipasa J, Elliott S, Xu H, Good MF (2002) Immunity to asexual blood stage
malaria and vaccine approaches. Immunol Cell Biol 80: 401–414.
22. Bull PC, Marsh K (2002) The role of antibodies to Plasmodium falciparum-infected-
erythrocyte surface antigens in naturally acquired immunity to malaria. Trends
Microbiol 10: 55–58.
23. Arevalo-Herrera M, Herrera S (2001) Plasmodium vivax malaria vaccine
development. Mol Immunol 38: 443–455.
24. Cole-Tobian JL, Cortes A, Baisor M, Kastens W, Xainli J, et al. (2002) Age-
acquired immunity to a Plasmodium vivax invasion ligand, the duffy binding
protein. J Infect Dis 186: 531–539.
25. Michon P, Fraser T, Adams JH (2000) Naturally acquired and vaccine-elicited
antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding
protein. Infect Immun 68: 3164–3171.
26. King CL, Michon P, Shakri AR, Marcotty A, Stanisic D, et al. (2008) Naturally
acquired Duffy-binding protein-specific binding inhibitory antibodies confer
protection from blood-stage Plasmodium vivax infection. Proc Natl Acad Sci U S A
105: 8363–8368.
27. Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, et al. (2009)
Immunoglobulin G subclass-specific responses against Plasmodium falciparum
merozoite antigens are associated with control of parasitemia and protection
from symptomatic illness. Infect Immun 77: 1165–1174.
28. D’Ombrain MC, Robinson LJ, Stanisic DI, Taraika J, Bernard N, et al. (2008)
Association of early interferon-gamma production with immunity to clinical
malaria: a longitudinal study among Papua New Guinean children. Clin Infect
Dis 47: 1380–1387.
29. Robinson LJ, D’Ombrain MC, Stanisic DI, Taraika J, Bernard N, et al. (2009)
Cellular TNF, IFN-c and IL-6 responses: correlates of immunity and risk of
clinical Plasmodium falciparum malaria in children from Papua New Guinea. Infect
Immun 77: 3033–3043.
30. McNamara DT, Kasehagen LJ, Grimberg BT, Cole-Tobian J, Collins WE, et al.
(2006) Diagnosing infection levels of four human malaria parasite species by a
polymerase chain reaction/ligase detection reaction fluorescent microsphere-
based assay. Am J Trop Med Hyg 74: 413–421.
31. McNamara DT, Thomson JM, Kasehagen LJ, Zimmerman PA (2004)
Development of a multiplex PCR-ligase detection reaction assay for diagnosis of
infection by four human malaria parasite species. J Clin Microbol 42: 2403–2410.
32. Mu¨ller I, Genton B, Rare L, Kiniboro B, Kastens W, et al. Three different
Plasmodium species show similar patterns of clinical tolerance of malaria infection.
Malar J. (in press).
33. Phimpraphi W, Paul RE, Yimsamran S, Puangsa-art S, Thanyavanich N, et al.
(2008) Longitudinal study of Plasmodium falciparum and Plasmodium vivax in a
Karen population in Thailand. Malar J 7: 99.
34. Luxemburger C, Thwai KL, White NJ, Webster HK, Kyle DE, et al. (1996) The
epidemiology of malaria in a Karen population on the western border of
Thailand. Trans R Soc Trop Med Hyg 90: 105–111.
35. Mendis K, Sina BJ, Marchesini P, Carter R (2001) The neglected burden of
Plasmodium vivax malaria. Am J Trop Med Hyg 64: 97–106.
36. Collins WE, Jeffery GM, Roberts JM (2004) A retrospective examination of the
effect of fever and microgametocyte count on mosquito infection on humans
infected with Plasmodium vivax. Am J Trop Med Hyg 70: 638–641.
37. Graves PM, Burkot TR, Carter R, Cattani JA, Lagog M, et al. (1988)
Measurement of malarial infectivity of human populations to mosquitoes in the
Madang area, Papua, New Guinea. Parasitology 96 (Pt 2): 251–263.
38. Bockarie MJ, Alexander N, Bockarie F, Ibam E, Barnish G, et al. (1996) The late
biting habit of parous Anopheles mosquitoes and pre-bedtime exposure of
humans to infective female mosquitoes. TransRSocTropMedHyg 90: 23–25.
39. Bockarie MJ, Dagoro H (2006) Are insecticide-treated bednets more protective
against Plasmodium falciparum than Plasmodium vivax-infected mosquitoes? Malar J
5: 15.
40. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, et al. (2008) A trial of
combination antimalarial therapies in children from Papua New Guinea.
N Engl J Med 359: 2545–2557.
41. Lengeler C (2004) Insecticide-treated bed nets and curtains for preventing
malaria. Cochrane Database Syst Rev 2: CD000363.
42. Luxemburger C, Perea WA, Delmas G, Pruja C, Pecoul B, et al. (1994)
Permethrin-impregnated bed nets for the prevention of malaria in schoolchil-
dren on the Thai-Burmese border. Trans R Soc Trop Med Hyg 88: 155–159.
43. Muller I, Smith T, Mellor S, Rare L, Genton B (1998) The effect of distance
from home on attendance at a small rural health centre in Papua New Guinea.
Int J Epidemiol 27: 878–884.
44. Muller O, Traore C, Becher H, Kouyate B (2003) Malaria morbidity, treatment-
seeking behaviour, and mortality in a cohort of young children in rural Burkina
Faso. Trop Med Int Health 8: 290–296.
45. Beeson JG, Brown GV (2002) Pathogenesis of Plasmodium falciparum malaria: the
roles of parasite adhesion and antigenic variation. Cell Mol Life Sci 59: 258–271.
46. Craig A, Scherf A (2001) Molecules on the surface of the Plasmodium falciparum
infected erythrocyte and their role in malaria pathogenesis and immune evasion.
Mol Biochem Parasitol 115: 129–143.
47. Vestergaard LS, Lusingu JP, Nielsen MA, Mmbando BP, Dodoo D, et al. (2008)
Differences in human antibody reactivity to Plasmodium falciparum variant surface
antigens are dependent on age and malaria transmission intensity in
northeastern Tanzania. Infect Immun 76: 2706–2714.
48. Scherf A, Lopez-Rubio JJ, Riviere L (2008) Antigenic variation in Plasmodium
falciparum. Annu Rev Microbiol 62: 445–470.
49. Fernandez-Becerra C, Yamamoto MM, Vencio RZ, Lacerda M, Rosanas-
Urgell A, et al. (2009) Plasmodium vivax and the importance of the subtelomeric
multigene vir superfamily. Trends Parasitol 25: 44–51.
50. Cowman AF, Crabb BS (2006) Invasion of red blood cells by malaria parasites.
Cell 124: 755–766.
Malaria in Young PNG Children
PLoS ONE | www.plosone.org 15 February 2010 | Volume 5 | Issue 2 | e9047
